Management of CKD Without Hypertension When Patient Refuses ARB
If your patient with CKD refuses an ARB, initiate an SGLT2 inhibitor immediately—this is now a 1A recommendation for CKD management regardless of diabetes status or blood pressure, and does not require hypertension as an indication 1.
Primary Recommendation: SGLT2 Inhibitors as First-Line Alternative
The 2024 KDIGO guidelines fundamentally changed CKD management by elevating SGLT2 inhibitors to a cornerstone therapy independent of traditional blood pressure control. Here's the algorithmic approach:
When to Start SGLT2i (in order of strength):
Strongest indications (1A recommendation):
- eGFR ≥20 mL/min/1.73m² AND urine ACR ≥200 mg/g 1
- Any heart failure, regardless of albuminuria level 1
- Type 2 diabetes with eGFR ≥20 mL/min/1.73m² 1
Moderate indication (2B recommendation):
- eGFR 20-45 mL/min/1.73m² with ACR <200 mg/g 1
Critical Implementation Points:
- Continue SGLT2i even if eGFR drops below 20 after initiation, unless intolerance or dialysis starts 1
- The initial eGFR dip is expected and hemodynamically beneficial—do not stop therapy 1
- Withhold only during prolonged fasting, surgery, or critical illness (ketosis risk) 1
Secondary Consideration: ACE Inhibitors
If the patient specifically refuses ARBs but not all RAS inhibition, offer an ACE inhibitor instead. The KDIGO recommendations treat ACEi and ARBs as interchangeable for CKD protection 1:
ACEi Indications Based on Albuminuria:
- Severely increased albuminuria (A3): Strong recommendation (1B) 1
- Moderately increased albuminuria (A2): Weaker recommendation (2C) 1
- Normal/mildly increased albuminuria (A1): Only if other indications exist (e.g., heart failure with reduced ejection fraction) 1
Key caveat: Since your patient has no hypertension, the traditional "blood pressure lowering" rationale doesn't apply. The benefit here is purely renal protection through reduced intraglomerular pressure and anti-proteinuric effects. You must assess their albuminuria level to determine if ACEi is indicated.
Tertiary Option: Non-Steroidal MRA
For patients with persistent albuminuria despite SGLT2i (or if SGLT2i contraindicated), consider a non-steroidal mineralocorticoid receptor antagonist 1. The 2024 KDIGO guidelines suggest this for patients with CKD and albuminuria, though the evidence grade wasn't fully detailed in the provided excerpts. This represents an emerging disease-modifying strategy beyond traditional RAAS blockade 2.
Practical monitoring requirements:
- Check potassium proactively and frequently
- Use potassium binders if needed to maintain therapy rather than stopping 1, 2
- This is particularly relevant since your patient lacks hypertension-related potassium-wasting
What NOT to Do
Do not simply accept "no treatment" for CKD without hypertension. The paradigm has shifted: CKD itself—particularly with albuminuria—requires disease-modifying therapy regardless of blood pressure status. The evidence now shows SGLT2 inhibitors and RAS inhibition slow progression through mechanisms beyond blood pressure reduction 1, 2.
Do not default to calcium channel blockers or diuretics as monotherapy in normotensive CKD. These are adjunctive agents for blood pressure control, not primary renal protective therapies in the absence of hypertension 3, 4.
Addressing Patient Refusal
Explore the reason for ARB refusal specifically:
- If it's side effects (cough, angioedema): ACEi carries similar risks
- If it's cost or access: SGLT2i may be more acceptable
- If it's medication burden: SGLT2i provides broader cardio-renal protection with once-daily dosing
- If it's philosophical opposition to all medications: focus education on the 1A evidence for SGLT2i in preventing dialysis and cardiovascular death
The strongest evidence supports SGLT2 inhibitors as the most robust alternative when RAS inhibition is refused or contraindicated 1, 2. This represents the most significant advance in CKD management in the past decade and does not require hypertension as a prerequisite.